<unk>  is an antineoplastic agent that is FDA approved for the treatment of newly diagnosed glioblastoma multiforme (GBM) and refractory anaplastic astrocytoma.   Common adverse reactions include alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, convulsions, rash, hemiparesis, diarrhea, asthenia, fever, dizziness, incoordination, viral infection, amnesia, and insomnia.
Temozolomide
Carmustine 
Vincristine sulfate
Fotemustine
Bendamustine
Lomustine
Ifosfamide
Trifluridine